Results
- Showing results for:
- Reset all filters
Search results
-
Conference paperAllegretti JR, Kelly C, Grinspan AM, et al., 2020, , Publisher: Ovid Technologies (Wolters Kluwer Health), Pages: S326-S326, ISSN: 0002-9270
-
Journal articleIaniro G, Segal JP, Mullish BH, et al., 2020, , Future Microbiology, ISSN: 1746-0913
-
Journal articleSegal JP, Mullish BH, Quraishi MN, et al., 2020, , Therapeutic Advances in Gastroenterology, Vol: 13, Pages: 1-14, ISSN: 1756-2848
Faecal Microbiota transplantation is currently a recommended therapy for recurrent/refractory Clostridioides difficile infection. The success of FMT for CDI has led to interest in its therapeutic potential in many other disorders. The mechanisms that underpin the efficacy of FMT are not fully understood. Importantly, FMT remains a crucial treatment in managing CDI and hence understanding the mechanisms that underpin its success will be critical to improve its clinical efficacy, safety and usability. Furthermore, a deeper understanding may allow us to expose FMT’s full potential as a therapeutic tool for other disease states. This review will explore the current understanding of the mechanisms underlying the efficacy of FMT across a variety of diseases.
-
Journal articleIaniro G, Mullish BH, Kelly CR, et al., 2020, , Gut, Vol: 69, Pages: 1555-1563, ISSN: 0017-5749
<jats:p> The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of <jats:italic>Clostridioides difficile</jats:italic> infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities. </jats:p>
-
Journal articleSegal JP, Mullish BH, Quraishi MN, et al., 2020, , Alimentary Pharmacology & Therapeutics, Vol: 52, Pages: 556-557, ISSN: 0269-2813
<jats:p><jats:bold>LINKED CONTENT</jats:bold></jats:p><jats:p>This article is linked to Lahtinen et al papers. To view these articles, visit<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15810">https://doi.org/10.1111/apt.15810</jats:ext-link> and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.1111/apt.15875">https://doi.org/10.1111/apt.15875</jats:ext-link>.</jats:p>
-
Journal articleMcIlroy JR, Mullish BH, Goldenberg SD, et al., 2020, , Clinical Immunology, ISSN: 1521-6616
-
Journal articleVieira-Silva S, Falony G, Belda E, et al., 2020, , NATURE, Vol: 581, Pages: 310-+, ISSN: 0028-0836
- Cite
- Citations: 201
-
Conference paperGhani R, Mullish BH, McDonald JA, et al., 2020, , Publisher: Elsevier BV, ISSN: 0016-5085
-
Conference paperMartinez-Gili L, McDonald JA, Liu Z, et al., 2020, , Publisher: Elsevier BV, Pages: S-138-S-139, ISSN: 0016-5085
-
Journal articleAllegretti JR, Hurtado J, Carrellas M, et al., 2020, , Gastroenterology, Vol: 158, Pages: S-22, ISSN: 0016-5085
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.
General enquiries
For any enquiries about the Microbiome Network at 911今日黑料, please contact: